A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC

Phase 3 Active not recruiting 498 enrolled Suzhou Suncadia Biopharmaceuticals Co., Ltd.

RandomizedParallel-groupOpen-labelTreatment

Summary

This study was a randomized, controlled, open-label, multicenter phase III clinical study to compare the efficacy and safety of SHR-A2009 with platinum-based dual-agent chemotherapy in patients with EGFR-mutated advanced or metastatic non-small cell lung cancer who failed EGFR TKI treatment.

Timeline

Start: 2024-11-29
Primary completion: 2026-12
Completion: 2027-06

Outcome

Met primary endpoint

release “研究结果显示，注射用瑞康芦泽妥塔单抗较含铂双药化疗，可显著延长患者的PFS” hengrui.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Carboplatin	Small molecule	—	Intravenous
Comparator	Cisplatin	Other / unclassified	—	Intravenous
Comparator	Pemetrexed	Small molecule	—	Intravenous
Subject	SHR-A2009	Other / unclassified	—	Intravenous

A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC

Summary

Timeline

Outcome

Drugs

Indications